Becton, Dickinson and Company (NYSE:BDX) Shares Bought by Marion Wealth Management

Marion Wealth Management increased its position in Becton, Dickinson and Company (NYSE:BDX) by 7.6% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 10,341 shares of the medical instruments supplier’s stock after buying an additional 726 shares during the quarter. Marion Wealth Management’s holdings in Becton, Dickinson and Company were worth $2,493,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently added to or reduced their stakes in the company. Livelsberger Financial Advisory acquired a new stake in Becton, Dickinson and Company during the 4th quarter worth approximately $27,000. Scarborough Advisors LLC acquired a new position in shares of Becton, Dickinson and Company during the 4th quarter valued at $32,000. Rise Advisors LLC acquired a new stake in Becton, Dickinson and Company in the 1st quarter valued at $38,000. Opal Wealth Advisors LLC purchased a new position in Becton, Dickinson and Company in the second quarter valued at about $45,000. Finally, Abound Wealth Management lifted its stake in shares of Becton, Dickinson and Company by 96.0% during the second quarter. Abound Wealth Management now owns 196 shares of the medical instruments supplier’s stock worth $46,000 after purchasing an additional 96 shares in the last quarter. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Becton, Dickinson and Company Trading Down 0.3 %

NYSE:BDX opened at $237.46 on Tuesday. The company has a market cap of $68.63 billion, a PE ratio of 52.30, a P/E/G ratio of 1.92 and a beta of 0.42. The business’s 50 day moving average is $236.66 and its two-hundred day moving average is $235.54. The company has a quick ratio of 1.36, a current ratio of 1.85 and a debt-to-equity ratio of 0.70. Becton, Dickinson and Company has a 52 week low of $218.75 and a 52 week high of $269.52.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings results on Thursday, August 1st. The medical instruments supplier reported $3.50 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.31 by $0.19. The firm had revenue of $4.99 billion during the quarter, compared to analyst estimates of $5.08 billion. Becton, Dickinson and Company had a return on equity of 14.49% and a net margin of 7.13%. The firm’s quarterly revenue was up 2.3% on a year-over-year basis. During the same period last year, the company posted $2.96 EPS. On average, analysts predict that Becton, Dickinson and Company will post 13.1 EPS for the current year.

Becton, Dickinson and Company Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, September 30th. Shareholders of record on Monday, September 9th were paid a dividend of $0.95 per share. The ex-dividend date was Monday, September 9th. This represents a $3.80 annualized dividend and a yield of 1.60%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is presently 83.70%.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on BDX shares. Evercore ISI raised their target price on Becton, Dickinson and Company from $286.00 to $290.00 and gave the company an “outperform” rating in a report on Tuesday, October 1st. Stifel Nicolaus boosted their target price on shares of Becton, Dickinson and Company from $270.00 to $280.00 and gave the stock a “buy” rating in a research report on Friday, July 26th. Raymond James dropped their price target on shares of Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating on the stock in a research note on Friday, August 2nd. Citigroup raised shares of Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and upped their price objective for the company from $255.00 to $275.00 in a research report on Tuesday, October 1st. Finally, StockNews.com raised Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research report on Thursday, August 8th. Nine analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $282.63.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.